Cell therapies for liver diseases

Yu, Yue; Fisher, James E.; Lillegard, Joseph B.; Rodysill, Brian; Amiot, Bruce; Nyberg, Scott L.

doi:10.1002/lt.22467

Cited by 89 publications

(85 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These early studies were useful in that in many cases it was possible to demonstrate a degree of biochemical improvement, or improvement in neurological status and hepatic encephalopathy. Unfortunately, however, early studies failed to demonstrate an improvement in overall survival and none of these techniques was proven through prospective randomised trials [18,19].…”

Section: Liver Transplantation and The Need For Alternative Therapiesmentioning

confidence: 96%

Hepatocyte cell therapy in liver disease

Bartlett

Newsome

2015

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Liver disease is a leading cause of morbidity and mortality. Liver transplantation remains the only proven treatment for end-stage liver failure but is limited by the availability of donor organs. Hepatocyte cell therapy, either with bioartificial liver devices or hepatocyte transplantation, may help address this by delaying or preventing liver transplantation. Early clinical studies have shown promising results, however in most cases, the benefit has been short lived and so further research into these therapies is required. Alternative sources of hepatocytes, including stem cell-derived hepatocytes, are being investigated as the isolation of primary human hepatocytes is limited by the same shortage of donor organs. This review summarises the current clinical experience of hepatocyte cell therapy together with an overview of possible alternative sources of hepatocytes. Current and future areas for research that might lead towards the realisation of the full potential of hepatocyte cell therapy are discussed.

show abstract

Section: Liver Transplantation and The Need For Alternative Therapiesmentioning

confidence: 96%

Hepatocyte cell therapy in liver disease

Bartlett

Newsome

2015

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

“…Therefore, alternative cellular resources may bridge patients until transplantation, or offer restoration of liver mass and function. Currently investigated cell sources include primary hepatocytes alone with the variety of SCs, including liver SCs, MSCs, BM-MNCs, ESCs and iPSCs [164].…”

Section: Liver Cirrhosismentioning

confidence: 99%

Cell-Based Therapy Approaches: The Hope for Incurable Diseases

Buzhor¹,

Leshansky²,

Blumenthal³

et al. 2014

Regen. Med.

146

105

View full text Add to dashboard Cite

Cell therapies aim to repair the mechanisms underlying disease initiation and progression, achieved through trophic effect or by cell replacement. Multiple cell types can be utilized in such therapies, including stem, progenitor or primary cells. This review covers the current state of cell therapies designed for the prominent disorders, including cardiovascular, neurological (Parkinson's disease, amyotrophic lateral sclerosis, stroke, spinal cord injury), autoimmune (Type 1 diabetes, multiple sclerosis, Crohn's disease), ophthalmologic, renal, liver and skeletal (osteoarthritis) diseases. Various cell therapies have reached advanced clinical trial phases with potential marketing approvals in the near future, many of which are based on mesenchymal stem cells. Advances in pluripotent stem cell research hold great promise for regenerative medicine. The information presented in this review is based on the analysis of the cell therapy collection detailed in LifeMap Discovery(®) (LifeMap Sciences Inc., USA) the database of embryonic development, stem cell research and regenerative medicine.

show abstract

“…These have included extracorporeal bioartificial liver devices8, 9, 10 and cell therapy 11, 12, 13. Along these lines, major progress has been made with the development of bioengineering models combining primary or stem cell‐derived cells by using three‐dimensional (3D) scaffolds attempting to reproduce the complexity of tissue architecture 14.…”

Section: Introductionmentioning

confidence: 99%

Liver tissue engineering: From implantable tissue to whole organ engineering

Mazza

Al‐Akkad

Rombouts

et al. 2017

Hepatology Communications

113

View full text Add to dashboard Cite

The term “liver tissue engineering” summarizes one of the ultimate goals of modern biotechnology: the possibility of reproducing in total or in part the functions of the liver in order to treat acute or chronic liver disorders and, ultimately, create a fully functional organ to be transplanted or used as an extracorporeal device. All the technical approaches in the area of liver tissue engineering are based on allocating adult hepatocytes or stem cell‐derived hepatocyte‐like cells within a three‐dimensional structure able to ensure their survival and to maintain their functional phenotype. The hosting structure can be a construct in which hepatocytes are embedded in alginate and/or gelatin or are seeded in a pre‐arranged scaffold made with different types of biomaterials. According to a more advanced methodology termed three‐dimensional bioprinting, hepatocytes are mixed with a bio‐ink and the mixture is printed in different forms, such as tissue‐like layers or spheroids. In the last decade, efforts to engineer a cell microenvironment recapitulating the dynamic native extracellular matrix have become increasingly successful, leading to the hope of satisfying the clinical demand for tissue (or organ) repair and replacement within a reasonable timeframe. Indeed, the preclinical work performed in recent years has shown promising results, and the advancement in the biotechnology of bioreactors, ex vivo perfusion machines, and cell expansion systems associated with a better understanding of liver development and the extracellular matrix microenvironment will facilitate and expedite the translation to technical applications. (Hepatology Communications 2018;2:131–141)

show abstract

Cell therapies for liver diseases

Cited by 89 publications

References 93 publications

Hepatocyte cell therapy in liver disease

Hepatocyte cell therapy in liver disease

Cell-Based Therapy Approaches: The Hope for Incurable Diseases

Liver tissue engineering: From implantable tissue to whole organ engineering

Contact Info

Product

Resources

About